Shanghai MicroPort Endovascular MedTech Obtains Medical Device Registration for Catheter

MT NewswiresDec 19 01:55 ET

Shanghai MicroPort Endovascular MedTech(Group)Co.,Ltd. (688016.SH): The peripheral balloon dilation catheter has obtained the medical instruments registration certificate.

According to Gelonghui on December 18, Shanghai MicroPort Endovascular MedTech(Group)Co.,Ltd. (688016.SH) announced that its holding subsidiary, Shanghai Lanmai Medical Technology Co., Ltd., has obtained the medical instruments registration certificate issued by the National Medical Products Administration, with the product name: peripheral balloon dilatation catheter. The acquisition of this medical instruments registration certificate further enriches the existing product categories of the company, expands the company's product line layout in the peripheral vein field, further promotes the company's market expansion in the peripheral field, continuously meets market demands, drives steady growth in the company's overall sales revenue and profit, and deepens the company's presence in the aortic and peripheral vascular intervention market.

Gelonghui FinanceDec 18 03:43 ET

Retail Investors Are Shanghai MicroPort Endovascular MedTech Co., Ltd.'s (SHSE:688016) Biggest Owners and Were Rewarded After Market Cap Rose by CN¥660m Last Week

Simply Wall StDec 15 19:29 ET

shanghai microport endovascular medtech(group)co.,ltd. (688016.SH) plans to launch an employee stock ownership plan in 2024.

shanghai microport endovascular medtech(group)co.,ltd. (688016.SH) announced the 2024 employee stock ownership plan (draft), the employee stock ownership plan...

Zhitong FinanceDec 4 08:53 ET

Shanghai MicroPort Endovascular MedTech to Pay Up to 70 Million Yuan in Back Taxes

MT NewswiresDec 3 03:22 ET

shanghai microport endovascular medtech(group)co.,ltd. may need to pay 70 million in back taxes after being disqualified as a high-tech enterprise.

shanghai microport endovascular medtech(group)co.,ltd. needs to pay up to 70 million yuan in back taxes due to the cancellation of its high-tech enterprise qualification certification, which is expected to account for more than 10% of the net income in the most recent fiscal year. shanghai microport endovascular medtech(group)co.,ltd. stated that it is currently communicating with relevant units regarding this matter; In addition, shanghai microport endovascular medtech(group)co.,ltd. previously revealed that without considering the impact of non-operating risk factors, the projected growth of the attributable net income in 2024 is around 0-10%.

cls.cnDec 3 03:08 ET